ENPP2 and idiopathic pulmonary fibrosis: Research teams, through a comprehensive literature review, have discovered that targeting ATX not only offers a novel approach to IPF treatment but also highlights its relevance in the pathogenesis of both IPF and COVID-19 related pulmonary complications.